Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

HOVON 178 WM: Treatment of Waldenstrom’s macroglobulinemia with epcoritamab if the disease comes back during or after previous treatment Pending

2025-522295-91-00 relapsed or refractory Waldenstrom’s macroglobulinemia 9
Impact of Biweekly and Triweekly Dosing Regimens Pending

2025-522305-38-00 Metastatic colorectal cancer 4
Optimizing subcutaneous FEntanyl titRation: RApid achievement of adequate exposure when treating cancer-Related paIn (FERRARI-study). Pending

2023-507355-30-00 Cancer pain 6
COLOMBE - A multicentre, single arm, phase 1/2 study, aiming to assess the safety and efficacy of nivolumab and imiquimod combination in vul… Pending

2025-524759-29-00 Vulvar Squamous Cell Carcinoma (VSCC) patients 9
DOSABEMA-Pharmacokinetic model of abemaciclib: correlation with severe diarrhea as the primary toxicity endpoint in patients with hormone re… Pending

2025-521696-31-00 HR+, HER2- breast cancer at high risk of recurrence 6
A study testing the new drug Lisaftoclax for newly diagnosed acute myeloid leukemia(GLORA-3) Pending

2024-516436-10-00 Acute myeloid leukemia 5
Next generation StaR-TREC Pending

2025-522955-25-00 Rectal cancer 6
FINACCESS - Finnish National Study for Early Access to Cancer Therapies Pending

2025-524769-26-00 Cancer 4
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti_Tumor Activity of AVZO-02… Pending

2024-517339-30-00 Advanced Solid Tumors 7
An open-label phase 2/3 study to analyse the feasibility and evaluate the safety of intravenous administration of 99mTc-PSMA-T4 in patients … Pending

2024-519358-35-00 Feasibility analysis and safety evaluation of [99mTc]Tc 10
Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or… Pending

2025-521126-15-00 Chronic Myeloid Leukemia 4
Phase 1/2 study to investigate the safety and preliminary efficacy of GSK5460025 alone or in combination with other anti-cancer agents in dM… Pending

2025-522318-21-00 Neoplasms, Colorectal 7
[18F]-olaparib PET; Molecular imaging of DNA damage response by [18F]-olaparib PET Pending

2024-511962-34-00 Head and neck squamous cell carcinoma (HNSCC) 7
Lantiolihaspuudutuksen vaikutus munuaisen poistoleikkauksen jälkeiseen kivun hoitoon ja toipumiseen Pending

2024-519910-30-00 Renal cancer 6
A Basket Trial of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies Pending

2025-523774-16-00 Advanced malignancies 9
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia Pending

2025-524810-28-00 Acute Promyelocytic Leukemia 5
Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts Pending

2023-503676-25-01 prostate cancer 4
Phase I, first-in-human clinical trial to evaluate safety of infusion of STAb-T19 cells: genetically modified T lymphocytes secreting αCD19x… Pending

2025-524814-27-00 Malignant B-cell neoplasms 1
18F-FES PET/MRI for tailoring treatment of luminal A and lobular breast cancer: a phase II trial evaluating the performance of FES PET/MRI i… Pending

2024-512465-14-00 Primary or advanced breast cancer LumA or ER+ Lobular s 4
APECS II: Comparing the efficacy of Pectoral Nerve (PECS II) Block with long-acting liposomal bupivacaine versus levobupivacaine for Mastect… Pending

2024-515183-30-00 Postoperative and chronic pain after breast cancer surg 5
Evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendoc… Pending

2024-515603-19-01 Localized digestive Neuroendocrine Carcinomas 4
An adaptive open-label multicentre phase 1/2 trial, to determine the recommended phase 2 dose of CCTx-001, and to assess safety, tolerabilit… Pending

2023-506865-71-00 Relapsed/Refractory Acute Myeloid Leukemia (AML) 7
A clinical trial of ifinatamab deruxtecan in people under age 18 who have certain types of cancer (MK-9999-01D) Pending

2025-522339-32-00 Neoplasm malignant 9
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies Pending

2024-518326-32-00 Patients with advanced solid malignancies that have pro 7